
3

Data from WHO and US Dept of HHS, 2017.
Showing the formation of arterial plaques when macrophages become foam cells due to oxidized cholesterol.
Our Lead Product: UDP-003 is a first-in-class drug; a specially engineered cyclodextrin which will target and remove toxic oxidized cholesterol, a key driver of atherosclerosis, neurodegenerative diseases, and other chronic diseases. UDP-003 is designed to restore the cardiovascular self-repair function and reduce arterial plaque.
Synthetic chemistry for cyclodextrins is very promising but also both extremely expensive and time consuming. So we built a proprietary discovery tool – The Cyclarity Platform. With it, we are able to model cyclodextrins and run virtual experiments, performing complex measurements of molecular-dynamic combinations between potential cyclodextrin forms and potential targets. Our tools can also run very broad-based docking analyses with these to test a variety of candidates against hundreds of possible on-target (and potential off-target) effects.
With an iterative process of improvement, the platform provides exceptional opportunities in a broad spectrum of molecular dynamics, including:
In developing The Cyclarity Platform, we are creating the possibilities to unlock the full potential of cyclodextrins. Our Head of Scientific Computing is also in the process of integrating AI into an iterative cyclodextrin construction program that will further accelerate our pipeline.
We’ve known since the 1990’s that heart disease is fundamentally driven by toxic oxidized cholesterol derivatives.
Showing how our cyclodextrins will remove oxidized cholesterol, thereby restoring the functionality of macrophages to clear plaques from arteries.
Cyclodextrins have a hydrophilic shell (attracted to and soluble in water), but a hydrophobic core (repels water and is non-polar). This means that our engineered cyclodextrins can attract and encapsulate hydrophobic molecules, and then contain them in a manner that can be dissolved in water, and thus purged from the bloodstream.
Unlike current drugs on the market and in development, our engineered cyclodextrins will be disease modifying – that is have the potential to reverse the course of cardiovascular disease. They will additionally server to prevent the onset of future pathologies, and will protect against the accumulation of oxidized cholesterol in the first place.
Protective | Preventative | Disease Modifying | |
---|---|---|---|
Statins | |||
PCSK9 Inhibitors | |||
ACE Inhibitors | |||
Blood thinners | |||
Fibrates | |||
CETP Inhibitors | |||
Generic Cyclodextrins | ![]() | ![]() | ![]() |
![]() |
Traditional drugs & animal models typically apply interventions far “upstream” (e.g., reduce the number of harmless circulating LDL particles, most of which will never be oxidized and contribute to atherosclerosis).
Cyclodextrins have countless industrial and pharmaceutical applications. Hydroxypropyl Beta Cyclodextrin is currently in clinical trials.
Cyclarity cyclodextrin derivatives have been designed to target only 7-ketocholesterol, the damaged cholesterol that actually drives atherosclerotic disease.
Our iterative process combines bench chemistry and computational modeling to design, test, and evaluate the potential efficacy of engineered cyclodextrins as candidate active pharmaceutical ingredients. We use molecular dynamics simulations to provide clear visuals demonstrating how various cyclodextrins form complexes with 7KC.
These simulations are then put to the test in the lab setting.
The potential for cyclodextrins to encapsulate molecules
We developed a platform that allows us to computationally reduce potential candidates to identify cyclodextrins that most conform to our desired goals. We can then physically synthesize these select engineered molecules for laboratory testing thereby significantly reducing the costs of discovery. Empirical data is then fed back into the platform to further optimize its ability to computationally predict molecular interactions, and with additional simulations, we are able to further optimize the end product, thus increasing efficacy while reducing any undesirable off-target effects.
Because of the hydrophilic / hydrophobic nature of our engineered cyclodextrins, they have the potential to be used for countless health, environmental, and industrial purposes to achieve molecular transport mechanisms previously unavailable.
Cyclarity was awarded one of the first ‘Innovation Passports’ under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) in 2021. The program provides enhanced early development input, accelerated assessment, rolling clinical reviews, and adaptive authorization.
We expect phase 1 trials to begin in 2024. Phase 2 readout should be complete in 2026. All our early stage trials will include imaging components to measure plaque impact.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | 1 year | Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . |
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
elementor | never | This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time. |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
_ga_V7N7F63JHL | 2 years | This cookie is installed by Google Analytics. |
_gat_UA-205714048-1 | 1 minute | A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to. |
_gid | 1 day | Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. |
CONSENT | 2 years | YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data. |
Cookie | Duration | Description |
---|---|---|
VISITOR_INFO1_LIVE | 5 months 27 days | A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface. |
YSC | session | YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages. |